Myriad, Janssen R&D ink research collaboration
January 2014
by  |  Email the author


SALT LAKE CITY—Myriad Genetics Inc. has announced that Janssen Research and Development LLC will be applying Myriad’s BRACAnalysis test in conjunction with the Phase 3 clinical trial of Yondelis for the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers. No financial terms were released. Yondelis, an antitumor drug, is currently approved for the treatment of advanced soft tissue sarcoma in Europe, Russia and South Korea.
“We are delighted to be collaborating with Janssen and applying our more than 20 years of BRCA-testing experience to help advance clinical cancer research,” Mark C. Capone, president of Myriad Genetics Laboratories, said in a news release. “A key element of our business strategy is to partner with major pharmaceutical companies to establish BRACAnalysis as the leading companion diagnostic, and this partnership is yet another important step toward that goal and the era of precision medicine and personalized healthcare.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.